INDIVIDUAL TEST 868
KCNA2 antibodies (IgG)
Indication
Suspected Autoimmune encephalitis or Atypical dementia.
Method
Cell-based assay (CBA), Indirect immunofluorescence(IIF). The method is not yet validated for clinical diagnostic use.
Reference interval
Serum
- <1:10 negative
CSF
- negative
Result
Results are reported as negative or positive. A positive result is followed by a titer (serum).
Interpretation
Autoantibodies against the potassium voltage-gated channel subfamily A 2 subunit (KCNA2), have been found in patients suffering from cognitive impairment, memory disturbance, and neuropsychiatric symptoms. Epileptic seizures, gait disorder, and ataxia have also been described.
References
- Arlt FA et al. Brain Behav Immun. 2024. KCNA2 IgG autoimmunity in neuropsychiatric diseases. PMID: 38309639.
- Timäus C et al. Brain Sci. 2021. KCNA2 Autoimmunity in Progressive Cognitive Impairment: Case Series and Literature Review. PMID: 33445475
Last updated: 2024-06-26
Can't find what you're looking for? We are here to help
ENSKILD ANALYS 868
KCNA2-antikroppar (IgG)
Indikation
Misstanke om autoimmun encefalit eller atypisk demens.
Metod
Cell-based assay (CBA), Indirekt immunofluorescens (IIF) Metoden är ännu inte validerad för klinisk diagnostik.
Referensintervall
Serum
- <1:10 negativt
Likvor
- negativt
Resultat
Resultat anges som negativt eller positivt. Positivt resultat titreras (serum).
Tolkning
Antikroppar mot kaliumkanalens subenhet A 2 (KCNA2) har rapporterats förekomma vid kognitiv påverkan med minnesrubbning och neuropsykiatriska symptom. Även fall med epilepsi, gångstörning och ataxi har rapporterats.
Förekomst av antikroppar mot KCNA2 i likvor är starkare associerat med kognitiv påverkan än seropositivitet.
Referenser
- Arlt FA et al. Brain Behav Immun. 2024. KCNA2 IgG autoimmunity in neuropsychiatric diseases. PMID: 38309639.
- Timäus C et al. Brain Sci. 2021. KCNA2 Autoimmunity in Progressive Cognitive Impairment: Case Series and Literature Review. PMID: 33445475
Senast uppdaterat: 2024-06-26